GLP1R and Stroke: Similarly, GLP1-RA is the only drug class that convincingly reduces the relative risk of stroke and cardiovascular death by 17% (HR, 0.83; 95% CI, 0.76–0.92; P < 0.001; P for heterogeneity, 0.77) and 13% (HR, 0.87; 95% CI, 0.81–0.94; P < 0.001; P for heterogeneity, 0.33), respectively, whereas finerenone has no effect (Figure S4 and S5 shows this in more detail [see Additional file 1]).